[REVISION HISTORY]

Sarcopenia Prevention and Muscle-Preserving Medical Trends

Updated 10 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-04 15:44 UTC → 2026-09-16 13:13 UTC · added ~~removed~~

By ~~early September~~ mid-September 2026, medical research has further clarified the systemic importance of muscle mass in healthy aging. Beyond physical strength, muscles are recognized as functioning as an endocrine organ that releases myokines, which assist in regulating blood sugar, reducing inflammation, and protecting the brain from dementia. A new international study led by Curtin University, analyzing over 80 studies across Australia, the United Kingdom, Canada, Thailand, and Italy, has found that sarcopenia—the age-related loss of muscle mass, strength, and physical function—is associated with a 42 percent increase in the risk of dementia. The research also identified a complex relationship between obesity and dementia risk: in obese individuals under 65, the risk increases by 9 percent, whereas in those aged 65 and older, the risk was 17 percent lower. Researchers cautioned that this does not imply weight gain is protective, and Professor Mario Siervo noted that further research is needed to see if low muscle mass combined with high body fat further elevates risk. To combat sarcopenia, experts recommend a three-pillar approach: progressive resistance ~~training to maintain fast-twitch muscle fibers,~~ training, increased protein intake (approximately 1.2 to 1.5 grams per kilogram of body weight for those over 50), and adequate ~~sleep for cellular repair.~~ sleep. A study in JAMA Network Open involving over 13,000 participants in Taiwan has established that simple mobility ~~assessments—including the single-leg stand, the chair stand test, and the Timed Up-and-Go test—are~~ assessments are highly effective predictors of life expectancy. As obesity medications gain popularity, the focus of weight loss evaluation is shifting from total kilograms lost to the preservation of muscle mass. To support this, new pharmacological interventions are in clinical testing. One experimental oral therapy, ENV-308 developed by Enveda, aims to mimic the hormone Lac-Phe released during intense exercise to prevent muscle loss in users of weight-loss injections. Additionally, monoclonal antibodies such as Apitegromab, Bimagrumab, and Trevogrumab are being studied for their ability to block proteins like myostatin and activin that inhibit muscle growth. While these drugs may minimize muscle loss, specialists emphasize they are not a replacement for physical exercise. Endocrinologist Patricia Gracitelli ~~notes~~ emphasizes that analyzing body composition is essential to ensure metabolic quality, a distinction particularly critical for women undergoing menopause, where declining estrogen levels can promote the loss of lean mass.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.